Heron Therapeutics Inc
Gesloten
SectorGezondheidszorg
0.33
Overzicht
Wijziging aandelenprijs
24u
Min
0.3
Max
0.36
Inkomsten | 2.6M -5.5M |
|---|---|
Verkoop | 3M 38M |
EPS | -0.03 |
Winstmarge | -14.573 |
Werknemers | 128 |
EBITDA | 2.1M -5.5M |
Volgende Winsten | 3 nov 2026 |
|---|
Marktkapitalisatie | -33M 63M |
|---|---|
Vorige openingsprijs | 0.33 |
Vorige sluitingsprijs | 0.33 |
Nieuwssentiment
By Acuity
81%
19%
316 / 340 Rangschikking in Healthcare
Heron Therapeutics Inc Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
Heron Therapeutics Inc Prognose
Sentiment
By Acuity
316 / 340 Rangschikking in Gezondheidszorg
Nieuwssentiment
Zeer Sterk Bearish Bewijs
Volatiliteit
Onder gemiddelde
Nieuws Volume (RCV)
Boven gemiddelde
Financieel
Verkoop- en administratiekosten
Bedrijfskosten
Winst voor belastingen
Verkoop
Kosten van verkopen
Brutowinst op verkopen
Rente-uitgaven op schulden
EBITDA
Operationele winst
$
Over Heron Therapeutics Inc
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
